anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This prospective, randomized, controlled and multi-center study was performed in 6 closed intensive care units (ICU) of academic tertiary hospitals. Adult patients with septic shock admitted to the hospitals from 2005 to 2008 were assigned to the study eligibility. Eligible patients were centrally randomized using sealed envelopes into one of the three groups which included lactate, ScvO2, and control groups. The criteria of septic shock included two of four criteria for the systemic inflammatory response syndrome and systolic blood pressure lower than 90 mmHg or decrease of systolic blood pressure more than 40 mmHg after fluid challenge and the clinical signs of tissue hypoperfusion, including oliguria, blood lactate concentration of 4 mmol/L or more and consciousness alteration. The patients were excluded if they meet any one of follows: an age of less than 18 years, pregnancy, an acute cerebral vascular event (Glasgow coma score \< 5), acute myocardial infarction or acute coronary syndrome, massive pulmonary embolism, status asthmaticus, a primary diagnosed cardiac dysrhythmias, contraindication to central venous catheterization, active gastrointestinal hemorrhage, massive intraabdominal infective focus without drainage, severe bronchopleural fistula, seizure, during chemotherapy or immunosuppressive therapy, or end stage of the diseases.

The protocol was approved by Institutional Ethics Committee. The informed consents were obtained from all patients or their legally authorized next of kin. The patients or their legal surrogate decision makers were informed of their right to refuse the study procedures at any time during the protocols were performed.

The case report forms (CRF) were sent to each site from the principal investigator with the protocols, which were randomly sealed in a serial of envelopes. After patients' enrollment, the CRFs were filled by the attending physicians at each site according to the protocol of each group. End points were 28-day mortality and in-hospital mortality until 90 days. The demographic data, acute physiological and chronic evaluation score (APACHE) II and other data from patients' basic condition were recorded at enrollment day. The protocol related data were collected at baseline and each hour for 6 hours and then at 12, 24, 36, 48, 60, 72 hours. The ICU and hospital length of stay were also noted and patients were followed up to day 28 and discharge from hospital for mortality. The protocol implementation and data collection stopped when patients or their families wished to withdraw from the program or refuse further treatment or a patient's death.
Effective solutions are needed to address the parallel persistence of a quality chasm and racial disparities in diabetes care. Many large health care systems are adopting components of the Chronic Care Model to achieve substantial gains in diabetes care, though few health systems have successfully incorporated elements specific to minority health. We have previously identified racial disparities in key diabetes outcomes measures within an integrated health care delivery system, Harvard Vanguard Medical Associates (HVMA). This project will use a randomized, controlled study design within HVMA to evaluate whether enhancements to the Chronic Care Model can produce significant improvement in the quality of diabetes care for black patients. Intervention clinicians will receive monthly panel-level disparities report cards, health navigation training, and cultural competency training, while control clinicians will function within the context of the generic Chronic Care Model. The study will occur over a 12 month period and involve 4,000 white patients and 2,500 black patients with diabetes receiving care at 8 health centers. The primary outcomes will include rates of glucose (HbA1c \<7.0), LDL cholesterol (\<100 mg/dL), and blood pressure (\<130/80) control. We will use patient focus groups to identify significant barriers to care and guide health navigation training. We will survey clinicians pre- and post intervention to assess the effect of the intervention on knowledge and attitudes towards disparities. Patient experiences will be assessed pre- and post-intervention using a validated instrument to determine whether the intervention can reduce existing racial disparities in patient reports of quality. We will perform a cost analysis related to the intervention using a health system perspective. In summary, this project will provide health systems with a rigorous analysis of a defined set of tools to improve diabetes care for minority populations.
The proposed research intends to construct a set of tissue microarrays containing different types of lung cancer tissues for the study of genes associated with lung cancer. In this study, lung tissue arrays will be generated using paraffin embedded archival tissues containing adjacent normal tissues and tumors from approximately 300 non-small cell lung cancers and 100 neuroendocrine tumors of the lung. Corded tissues of 0.6 um in diameter will be taken from each tumor and arrayed onto recipient paraffin blocks to generate a lung tumor specific microarray. Four-micrometer thickness sections will be cut from the tissue array and used to survey gene expression status in arrayed tumors using fluorescence in situ hybridization (FISH, in situ hybridization, and/or immunohistochemistry methods. Additionally, approximately 20 sections will be cut from each primary tumor block to isolate genomic DNA for the analysis of genetic changes in the arrayed tumor samples. The goals of this proposal are 1) to generate a single tissue block containing multiple tumors, 2) allow rapid and efficient analysis of gene expressions in a large number of samples using a single tissue section, and 3) to correlate the molecular changes in the tumors with the clinical and pathological features of the disease. Due to the experimental nature of the research and the fact that all tumors obtained are archival tissues at AFIP, the investigators will not report the result of gene expression back to the subject.

To date, all samples needed for the protocol have been reached and there will be no more patient accrual but survival status of the patients as well as molecular analysis using the constructed lung tissue microarrays will continue for the foreseeable future.
Atrial fibrillation (AF) and hypertension are among the main treatable risk factors for ischemic stroke and transient ischemic attack (TIA). Detecting paroxysmal atrial fibrillation in stroke patients is challenging, but highly relevant since anticoagulation can effectively reduce the risk of recurrent strokes. Furthermore, hypertension remains poorly controlled even after stroke despite multiple available treatment options. In the CARDIOSTROKE trial, the investigators aim to randomize 405 patients with recent ischemic stroke or TIA into (1) standard diagnostic work-up, follow-up and treatment (control group) and (2) 3-week ECG monitoring to detect occult AF and self-monitoring of blood pressure with mobile-device-assisted self-titration of antihypertensive medication (intervention group). Randomization will occur 2:1 into control and intervention groups. The co-primary outcomes include (1) incidence of new-onset AF and (2) difference in the mean blood pressure at 12-months.
PCT No. PCT/FR96/01181 Sec. 371 Date Mar. 27, 1997 Sec. 102(e) Date Mar. 27, 1997 PCT Filed Jul. 25, 1996 PCT Pub. No. WO97/04861 PCT Pub. Date Feb. 13, 1997A method for making solid granules containing aromatic, nutritional, dietary or cosmetic substances, wherein a core consisting of excipients optionally combined with active substances is formed for use as a carrier, and the core is coated in three steps with at least one layer, with one layer being formed in each step, by (a) coating the core with active substances optionally combined with excipients, (b) drying the layer and (c) screening the coated core. The method is preferably used to make granules that contain plant extracts and essential oils and may be chewed, sucked, swallowed or dissolved.
The authors will enroll a control group of 30 women, age- matched with the PCOS women, from consecutive women controlled in the same outpatient clinic who met the following inclusion criteria: history of irregular menstrual cycle in absence of severe gynecologic and non-gynecologic diseases. This PCOS sample will be entirely constituted by women with no pregnancy desire; therefore, with the aim to limit the potential effect of the unfulfilled wish to conceive in the final results; additionally, infertile women will not admitted into the control group.
Disclosed is a method and apparatus for processing pharmaceutical orders to determine whether a buyer of pharmaceuticals qualifies for an “own use” discount. “Own use” discounts on pharmaceuticals are available for a limited class of buyers under 35 U.S.C. §13c. Under one method, an auditor receives an order for a quantity of pharmaceuticals, receives a report associated with the order containing sufficient information therein to perform an audit on the order, and compares the information found in the order with the information found in the associated report to make a status determination as to whether a buyer qualifies for an “own use” discount. Preferably a second report containing additional audit information is received as well. The auditor can also audit the order by comparing the order to this additional information. If these comparisons result in a determination that the buyer does in fact qualify for an “own use” discount, the auditor can then place the order with a pharmaceutical seller for a discounted price. Also disclosed is a pharmaceutical order auditing system that uses a computer to perform the above-described audit.
The present invention discloses a black plaster and a preparation process thereof. The black plaster is composed of sesame oil, pig bone, crinis ustus, coralbean bark, suberect spatholobus, putamen manidis and yellow lead. The components are decocted to form the plaster. The plaster has a specially good effect and a miraculous effect on preventing septicemia and healing wounds, and patients can not feel pain. By using the present invention, bouton superficial infection can be recovered in 7 to 8 days in common, the cervical vertebra pain can be eliminated in 7 to 8 days by using the present invention, tumors of hyperplasia of mammary glands can be eliminated in about 10 days, and the incised wound can be healed in 3 to 5 days. The present invention has the characteristics of good therapeutic effects of eliminating swelling, removing toxic substance, alleviating pain and healing wound, obvious effect, low price and wide range of application.
PURPOSE:To prepare a cosmetic packing agent having rapid drying characteristics, and excellent releasability of the formed film after use, by using a modified polyvinyl alcohol obtained by making a part of OH of polyvinyl alcohol hydrophobic with a silylating agent, as a film-forming material. CONSTITUTION:A polyvinyl alcohol having a residual acetic acid group content of <=25mol%, is made to react with a silylating agent to obtain a modified polyvinyl alcohol wherein the content of unreacted OH is 70-90mol%, the sum of acetic acid group and the group reacted with the silylating group is 30-10mol%, and the content of the group reacted with the silylating group is >=5mol%. The modified polyvinyl alcohol is used as a film-forming material of a cosmetic packing agent. The film-forming material may contain <=70wt% of unmodified polyvinyl alcohol. The packing agent thus prepared can be easily applied to the skin, and dried rapidly. The formed film can be released from the skin completely and easily, without causing pain or pulling feelings to the skin.
INTRODUCTION: Micturition physiology differs in men and women. However, the results in standard urodynamic studies in women with lower urinary tract symptoms (LUTS) were extrapolated from studies in men. Nowadays, the only validated nomogram for females is Solomon-Greenwell's. However, it only evaluated bladder outlet obstruction (BOO) without considering detrusor underactivity (DU). This study aims to create a nomogram that includes an evaluation of DU and BOO in nonneurogenic women and validate it against videourodynamic studies along with other nomograms.
MATERIALS AND METHODS: For the first analysis (creation cohort), we included 183 women with LUTS who underwent videourodynamic study between 2022 and 2023. Exclusion criteria were females with neurologic diseases, renal transplantation, and trouble performing the flow-pressure study. Baseline characteristics of the patients, urodynamic parameters, and classifications on different nomograms and indexes were evaluated. A logistic regression found Qmax and PdetQmax as predictors for DU and BOO. The Barco-Castillo nomogram was created by clustering analysis and adjusted by the results of the logistic regression. A second (test) cohort was evaluated from 2023 to 2024, including 142 patients for the validation of the nomogram. A p < 0.05 was considered significant.
RESULTS: All urodynamic parameters were compared between both cohorts, with no significant differences. The median age of the creation cohort was 50 years old (interquartile range [IQR] 39-63). All patients had LUTS and a previous standard urodynamic study without a clear diagnosis. The cluster analysis had a p < 0.05 for two groups of BOO (yes/no) and two of DU (yes/no). We created the graph based on the logistic regression results and adjusted it according to the data. The median age of the test cohort was 44 years old (IQR 33.75-59) and had the same indication for the videourodynamic study. The receiver operating characteristic (ROC) curve for BOO showed an accuracy of 85.4% for Barco-Castillo nomogram, 68.5% for Blaivas-Groutz, 58.1% for Solomon-Greenwell, 57.1% for BOOI, and 50% for LinPURR. For DU, accuracy was 80.5% for PIP-1, 80.2% for Barco-Castillo, 76.6% for BCI, and 70.1% for LinPURR.
CONCLUSIONS: When evaluating women's urodynamic studies, it is important to focus on female physiology and discourage the use of parameters previously standardized in men. We encourage using the new Barco-Castillo nomogram to determine BOO and DU in women as the currently easiest and more accurate tool.
Single PVSRIPO infusion at a dose of 5x10\^7 tissue culture infected dose (TCID50). Atezolizumab infusions at a dose of 1200 mg every three weeks for up to two years.
Enalapril maleate has been evaluated for safety in more than 10,000 patients, including over 1000 patients treated for one year or more. Enalapril maleate has been found to be generally well tolerated in conrolled clinical trials involving 2987 patients.  


For the most part, adverse experiences were mild and transient in nature. In clinical trials, discontinuation of therapy due to clinical adverse experiences was required in 3.3 percent of patients with hypertension and in 5.7 percent of patients with heart failure. The frequency of adverse experiences was not related to total daily dosage within the usual dosage ranges. In patients with hypertension the overall percentage of patients treated with enalapril maleate reporting adverse experiences was comparable to placebo.
The complete cDNA cloning of two human genes previously designated flg and bek is disclosed. These genes encode for two similar but distinct surface receptors comprised of an extracellular domain with three immunoglobulin-like regions, a single transmembrane domain, and a cytoplasmic portion containing a tyrosine kinase domain with a typical kinase insert. The expression of these two cDNAs in transfected NIH-3T3 cells led to the biosynthesis of proteins of 150 kDa and 135 kDa for flg and bek respectively. Direct binding experiments with radiolabeled acidic FGF (aFGF), basic FGF (bFGF), or kFGF inhibition of binding with native growth factors, and Scatchard analysis of the binding data indicated that bek and flg bind aFGF, bFGF, or kFGF with dissociation constants of (2-15)x10-11M. The high affinity binding of three distinct growth factors to each of two different receptors represents a unique double redundancy without precedence among polypeptide growth factor/receptor interactions. The use of transformed host cells overexpressing flg or bek or biologically active fragments thereof for drug screening is disclosed.
Improved mammalian virus vaccines are combinations that contain an immunogenic amount of inactivated virus, (such as influenza virus, Herpes varicella virus, measles virus, Epstein Barr virus, respiratory syncytial virus, parainfluenza 3, Herpes simplex type 1 virus and Herpes simplex type 2 virus) and an immunogenic amount of a purified recombinant envelope protein from the virus, or a fragment or precursor of the protein. Alternatively, they contain either inactivated virus and/or envelope protein antigens and an adjuvant such as granulocyte-macrophage colony stimulating factor. One embodiment of an influenza vaccine is prepared by combining inactivated virus, (preferably three strains of the virus), and hemagglutinin, preferably a combination of respective hemagglutinins for each of the three strains present. In another embodiment, an influenza vaccine is prepared by combining inactivated virus, again (preferably three strains of the virus), and neuraminidase, (preferably a combination of respective neuraminidase for each of the three strains present). In a third embodiment, the vaccine contains inactivated virus and both hemagglutinin and neuraminidase, preferably using three strains of each. Granulocyte-macrophage colony stimulating factor is optionally added to these embodiments.
MSA is a progressive, fatal disorder characterized by autonomic failure and parkinsonism and/or cerebellar involvement. Neuropathologically, MSA is characterized by glial cytoplasmic inclusions (GCI) of abnormally aggregated α-synuclein (α-syn). This was a study to test the hypothesis that Rifampicin, because of its ability to inhibit the formation of α-synuclein fibrils and disaggregate fibrils already formed, will delay progression or reverse neurologic and autonomic functions and symptoms in MSA. This approach has been proposed as a potential approach to treat parkinsonism and specifically, MSA. In an experimental model of MSA, it was hypothesized that Rifampicin would improve behavioral abnormalities of MSA and halt or reverse the pathological changes. The primary objective was to undertake a double-blind placebo-controlled clinical trial on the effect of Rifampicin on progression of neurological and autonomic failure in MSA.

The Data Safety Monitoring Board (DSMB) recommended stopping the study after an interim analysis of the primary endpoint revealed that futility criteria were met.
Transmissible gastroenteritis virus (TGEV) is characterized by watery diarrhea, vomiting, and dehydration and is associated with high mortality especially in newborn piglets, causing significant economic losses to the global pig industry. Hypoxia inducible factor-1α (HIF-1α) has been identified as a key regulator of TGEV-induced inflammation, but understanding of the effect of HIF-1α on TGEV infection remains limited. This study found that TGEV infection was associated with a marked increase in HIF-1α expression in ST cells and an intestinal organoid epithelial monolayer. Furthermore, HIF-1α was shown to facilitate TGEV infection by targeting viral replication, which was achieved by restraining type I and type III interferon (IFN) production. In vivo experiments in piglets demonstrated that the HIF-1α inhibitor BAY87-2243 significantly reduced HIF-1α expression and inhibited TGEV replication and pathogenesis by activating IFN production. In summary, we unveiled that HIF-1α facilitates TGEV replication by restraining type I and type III IFN production in vitro, ex vivo, and in vivo. The findings from this study suggest that HIF-1α could be a novel antiviral target and candidate drug against TGEV infection.
Systems and methods are provided for imaging a target anatomy of a patient. The systems and methods can include generating and updating a 3D model of the target anatomy. In some embodiments, the target anatomy can be a heart of the patient. The 3D model can be updated with image slices obtained with a catheter based imaging system, such as a TEE imaging system. In some examples, the images can be applied to a classifier to determine if the present view corresponds to a user-selected or desired view. The classifier score can be used to provide instructions to a control system to move the imaging system until the desired view is obtained.
Ypeginterferon alfa-2b,sc. Qw. 48 weeks. Granulocyte-macrophage colony stimulating factor,sc.qd, the first three day of every 28 days, starting from interferon treatment week 13.
1. Compounds of the general formula (I)   wherein A is a positive charged ion (cation) of a drug substance, X is a negative charged ion (anion) of sweetener -   and their solvates having organoleptically beneficial properties. 2. Compounds of the general formula (I) and their solvates according to Claim 1, characterized in that A is as determined in Claim 1, X means negative charged ion of the formulae             and their solvates. 3. Compounds of the general formula (I) and their solvates according to Claim 1, characterized in that A is a positive charged ion of drotaverin, prenoxdiazine, selegiline, azithromycin, cimetidine, ciprofloxacin, clopidogrel, irbesartan, erythromycin, fluoxetine, ranitidine, clarithromycin, enalapril. 4. Salt of drotaverin formed by the anion of the formula (1) and its solvates. 5. Salt of drotaverin formed by the anion of the formula (2) and its solvates. 6. Salt of drotaverin formed by the anion of the formula (3) and its solvates. 7. Salt of drotaverin formed by the anion of the formula (4) and its solvates. 8. Salt of drotaverin formed by the anion of the formula (5) and its solvates. 9. Salt of drotaverin formed by the anion of the formula (6) and its solvates. 10. Salt of prenoxdiazine formed by the anion of the formula (1) and its solvates. 11. Salt of prenoxdiazine formed by the anion of the formula (2) and its solvates. 12. Salt of prenoxdiazine formed by the anion of the formula (3) and its solvates. 13. Salt of prenoxdiazine formed by the anion of the formula (4) and its solvates. 14. Salt of prenoxdiazine formed by the anion of the formula (5) and its solvates. 15. Salt of prenoxdiazine formed by the anion of the formula (6) and its solvates. 16. Pharmaceutical preparations characterized in that, they contain at least one compound of the general formula (I), wherein A and X are as defined in Claim 1, and/or its/their solvates. 17. Pharmaceutical preparation according to Claim 16, characterized in that it is solid. 18. Pharmaceutical preparation according to Claim 16, characterized in that it is liquid. 19. Process for the preparation of compounds of the general formula (I), characterized in that, a cation form (positive charged ion) of a drug substance is reacted with an anion form (negative charged ion) of a sweetener. 20. Procedure according to Claim 19, characterized in that, the reaction is carried out in liquid medium. 21. An inhibitor for PDE-IV containing at least one of the compounds and/or their solvates according to Claims 4 to 9 as therapeutically active component. 22. Use of at least one of the compounds and/or their solvates according to Claims 4 to 9 for the preparation of pharmaceutical compositions for inhibiting PDE-IV enzime. 23. A spasmolytic agent containing at least one of the compounds and/or their solvates according to Claims 4 to 9 as therapeutically active component. 24. Use of at least one of the compounds and/or their solvates according to Claims 4 to 9 for the preparation of a spasmolytic pharmaceutical compositions.